Nadine Shehab

Nadine Shehab

Auto-generated profile, based on publicly available information

Nadine Shehab

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DBDaniel S. Budnitz
Daniel S. Budnitz
MLMaribeth C. Lovegrove
Maribeth C. Lovegrove
NSNadine Shehab
Nadine Shehab
CRChesley L. Richards
Chesley L. Richards
Adverse drug events are important preventable causes of hospitalization in older adults. However, nationally representative data on adverse drug events that result in hospitalization in this population have been limited.

4 December 2007 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DBDaniel S. Budnitz
Daniel S. Budnitz
NSNadine Shehab
Nadine Shehab
SKScott R. Kegler
Scott R. Kegler
CRChesley L. Richards
Chesley L. Richards
The Beers criteria identify inappropriate use of medications in older adults. The number of and risk for adverse events from these medications are unknown. To estimate the number of and risk for emergency department visits for adverse events involving Beers criteria medications compared with other medications. Nationally representative, public health surveillance of adverse drug events and a cross-sectional survey of outpatient medical visits. National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance System, 2004–2005; National Ambulatory Medical Care Survey, 2004; and National Hospital Ambulatory Medical Care Survey, 2004. Persons 65 years of age or older seeking emergency department and outpatient care. Estimated number of and risks for emergency department visits for adverse drug events involving Beers criteria medications and other medications. Among U.S. patients 65 years of age or older, an estimated 177 504 emergency department visits (95% CI, 100 155 to 254 854 visits) for adverse drug events occurred both years. An estimated 3.6% (CI, 2.8% to 4.5%) of these visits were for adverse events medications considered to be always potentially inappropriate, according to the Beers criteria, and 33.3% (CI, 27.8% to 38.7%) of visits were for adverse events from 3 other medications (warfarin [17.3%], insulin [13.0%], and digoxin [3.2%]). Accounting for outpatient prescription frequency, the risk for emergency department visits for adverse events due to these 3 medications was 35 times (CI, 9.6 to 61) greater than that for medications considered to be always potentially inappropriate. Adverse events were identified only in emergency departments. Compared with other medications, Beers criteria medications caused low numbers of and few risks for emergency department visits for adverse events. Performance measures and interventions targeting warfarin, insulin, and digoxin use could prevent more emergency department visits for adverse events.

27 November 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
DWDaniel M. Witt
Daniel M. Witt
RNRobby Nieuwlaat
Robby Nieuwlaat
NCNathan P. Clark
Nathan P. Clark
JAJack Ansell
Jack Ansell
AHAnne Holbrook
Anne Holbrook
GGGordon Guyatt
Gordon Guyatt
In July 2022, these guidelines were reviewed by an expert work group convened by ASH. Review included limited searches for new evidence and discussion of the search results. Following this review, the ASH Committee on Quality agreed to continue monitoring the supporting evidence rather than revise or retire these guidelines at this time. Limited searches and expert review will be repeated annually going forward until these guidelines are revised or retired. Background: Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in their decisions about the use of anticoagulants in the management of VTE. These guidelines assume the choice of anticoagulant has already been made. Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 25 recommendations and 2 good practice statements to optimize management of patients receiving anticoagulants. Conclusions: Strong recommendations included using patient self-management of international normalized ratio (INR) with home point-of-care INR monitoring for vitamin K antagonist therapy and against using periprocedural low-molecular-weight heparin (LMWH) bridging therapy. Conditional recommendations included basing treatment dosing of LMWH on actual body weight, not using anti–factor Xa monitoring to guide LMWH dosing, using specialized anticoagulation management services, and resuming anticoagulation after episodes of life-threatening bleeding.

15 October 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AGAndrew I. Geller
Andrew I. Geller
NSNadine Shehab
Nadine Shehab
NWNina J. Weidle
Nina J. Weidle
MLMaribeth C. Lovegrove
Maribeth C. Lovegrove
BWBeverly J. Wolpert
Beverly J. Wolpert
DBDaniel S. Budnitz
Daniel S. Budnitz
Dietary supplements, such as herbal or complementary nutritional products and micronutrients (vitamins and minerals), are commonly used in the United States, yet national data on adverse effects are limited. We used nationally representative surveillance data from 63 emergency departments obtained from 2004 through 2013 to describe visits to U.S. emergency departments because of adverse events related to dietary supplements. On the basis of 3667 cases, we estimated that 23,005 (95% confidence interval [CI], 18,611 to 27,398) emergency department visits per year were attributed to adverse events related to dietary supplements. These visits resulted in an estimated 2154 hospitalizations (95% CI, 1342 to 2967) annually. Such visits frequently involved young adults between the ages of 20 and 34 years (28.0% of visits; 95% CI, 25.1 to 30.8) and unsupervised children (21.2% of visits; 95% CI, 18.4 to 24.0). After the exclusion of unsupervised ingestion of dietary supplements by children, 65.9% (95% CI, 63.2 to 68.5) of emergency department visits for single-supplement–related adverse events involved herbal or complementary nutritional products; 31.8% (95% CI, 29.2 to 34.3) involved micronutrients. Herbal or complementary nutritional products for weight loss (25.5%; 95% CI, 23.1 to 27.9) and increased energy (10.0%; 95% CI, 8.0 to 11.9) were commonly implicated. Weight-loss or energy products caused 71.8% (95% CI, 67.6 to 76.1) of supplement-related adverse events involving palpitations, chest pain, or tachycardia, and 58.0% (95% CI, 52.2 to 63.7) involved persons 20 to 34 years of age. Among adults 65 years of age or older, choking or pill-induced dysphagia or globus caused 37.6% (95% CI, 29.1 to 46.2) of all emergency department visits for supplement-related adverse events; micronutrients were implicated in 83.1% (95% CI, 73.3 to 92.9) of these visits. An estimated 23,000 emergency department visits in the United States every year are attributed to adverse events related to dietary supplements. Such visits commonly involve cardiovascular manifestations from weight-loss or energy products among young adults and swallowing problems, often associated with micronutrients, among older adults. (Funded by the Department of Health and Human Services.)

15 September 2008 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
NSNadine Shehab
Nadine Shehab
PPPriti R. Patel
Priti R. Patel
ASArjun Srinivasan
Arjun Srinivasan
DBDaniel S. Budnitz
Daniel S. Budnitz
Background.Drug-related adverse events are an underappreciated consequence of antibiotic use, and the national magnitude and scope of these events have not been studied. Our objective was to estimate and compare the numbers and rates of emergency department (ED) visits for drug-related adverse events associated with systemic antibiotics in the United States by drug class, individual drug, and event type.

1 May 2014 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
AGAndrew I. Geller
Andrew I. Geller
NSNadine Shehab
Nadine Shehab
MLMaribeth C. Lovegrove
Maribeth C. Lovegrove
SKScott R. Kegler
Scott R. Kegler
KWKelly N. Weidenbach
Kelly N. Weidenbach
DBDaniel S. Budnitz
Daniel S. Budnitz
Insulin is a cornerstone of type 1 diabetes mellitus (DM) treatment and is increasingly introduced early in the treatment course for patients with type 2 DM, who account for 90% to 95% of new DM cases annually.1 During the last decade, the number of US patients with insulin-treated DM rose 50%; one-third of patients with diabetes currently use insulin,2 and in 2012, insulin was estimated to cost the US health care system approximately $6 billion.3 Tight glycemic control with insulin has been associated with reductions in disease complications among patients with type 1 DM4 but has been increasingly associated with harms among patients with type 2 DM.5-7 Insulin remains one of the most challenging and limiting aspects of DM medical management owing to complexities in dosing and administration, as well as the need for routine monitoring of blood glucose (BG) and food intake to avoid potentially fatal hypoglycemia.8 The risk of insulin-related hypoglycemia is an important consideration when choosing among treatment options and individualizing glycemic targets, particularly in patients for whom benefits of intensive control are not as likely to be realized.9,10